~~10/532,206~~ 10-664-165

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssspta1623hrr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	JAN 11	CA/CAPLUS - Expanded patent coverage to include Russia (Federal Institute of Industrial Property)

NEWS EXPRESS	JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

10458286

FILE 'HOME' ENTERED AT 15:14:17 ON 13 JAN 2005

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:14:28 ON 13 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JAN 2005 HIGHEST RN 811782-89-5
DICTIONARY FILE UPDATES: 11 JAN 2005 HIGHEST RN 811782-89-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\10664165.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,H,O,S,N

10458286

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 full
FULL SEARCH INITIATED 15:14:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

<  14.5% PROCESSED  252338 ITERATIONS  (     1 INCOMPLETE)    3115 ANSWERS

<  20.4% PROCESSED  354173 ITERATIONS  (     1 INCOMPLETE)    4837 ANSWERS

<  23.1% PROCESSED  400000 ITERATIONS  (     1 INCOMPLETE)    5511 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.41

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS   23432

L2         5511 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     162.19     162.40

FILE 'CAPLUS' ENTERED AT 15:16:00 ON 13 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 13 Jan 2005  VOL 142 ISS 3
FILE LAST UPDATED: 12 Jan 2005  (20050112/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l2
L3         615 L2

=> s l3 and sodium
        961054 SODIUM
L4          35 L3 AND SODIUM

=> s l3 and channels
        138103 CHANNELS
L5           1 L3 AND CHANNELS

=> s l3 and "cell membrane"
```

10458286

```
       1863637 "CELL"
        648064 "MEMBRANE"
        130812 "CELL MEMBRANE"
                 ("CELL"(W)"MEMBRANE")
L6           1 L3 AND "CELL MEMBRANE"

=> s l3 and blood vessel
       1167486 BLOOD
        198786 VESSEL
         83587 BLOOD VESSEL
                 (BLOOD(W)VESSEL)
L7          11 L3 AND BLOOD VESSEL

=> s  l2 full
L8         615 L2

=> s l8 and bladder
         29744 BLADDER
L9           8 L8 AND BLADDER

=> s l8 and bronchial tube
         14877 BRONCHIAL
        292134 TUBE
            36 BRONCHIAL TUBE
                 (BRONCHIAL(W)TUBE)
L10          0 L8 AND BRONCHIAL TUBE

=> s l8 and bronchial tube
         14877 BRONCHIAL
        292134 TUBE
            36 BRONCHIAL TUBE
                 (BRONCHIAL(W)TUBE)
L11          0 L8 AND BRONCHIAL TUBE

=> s l8 and neuronal cell
         88899 NEURONAL
       1863637 CELL
          7589 NEURONAL CELL
                 (NEURONAL(W)CELL)
L12          0 L8 AND NEURONAL CELL

=> s l8 and gastroinstestinal tract
            11 GASTROINSTESTINAL
        123036 TRACT
             1 GASTROINSTESTINAL TRACT
                 (GASTROINSTESTINAL(W)TRACT)
L13          0 L8 AND GASTROINSTESTINAL TRACT

=> s l5 or l6 or l7 or l9
L14         19 L5 OR L6 OR L7 OR L9

=> d bib abs l14

L14  ANSWER 1 OF 19  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:927010  CAPLUS
DN   141:376382
TI   Pin1-modulating compounds and methods of use for the treatment of
     Pin1-associated diseases, including cancer
IN   Bao, Lere; Kimzey, Amy
PA   Pintex Pharmaceuticals, Inc., USA
SO   PCT Int. Appl., 189 pp.
     CODEN: PIXXD2
```

10458286

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004093803	A2	20041104	WO 2004-US11957	20040416

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-463271P P 20030416

AB The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer. The present invention aims to provide photochemotherapeutic compds. with increased specificity as compared with known agents.

=> s bib abs 1-19 hitstr l14
MISSING OPERATOR HITSTR L14
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d bib abs 1-19 hitstr l14

L14 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:927010 CAPLUS
DN 141:376382
TI Pin1-modulating compounds and methods of use for the treatment of Pin1-associated diseases, including cancer
IN Bao, Lere; Kimzey, Amy
PA Pintex Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004093803	A2	20041104	WO 2004-US11957	20040416

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-463271P P 20030416

AB The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer. The present invention

NPA

aims to provide photochemotherapeutic compds. with increased specificity as compared with known agents.

IT **676649-27-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Pin1-modulating compds. for treatment of Pin1-associated diseases, including cancer)

RN 676649-27-7 CAPLUS

CN 3-Thiazolidinebutanoic acid, 5-[(1,2,3,4,4a,9,10,10a-octahydro-6,7-dimethoxy-3-methyl-2-phenanthrenyl)methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



L14 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:792843 CAPLUS

DN 141:421217

TI Effects of modification at the fifth residue of μ-conotoxin GIIIA with bulky tags on the electrically stimulated contraction of the rat diaphragm

AU Nakamura, M.; Ishida, Y.; Kohno, T.; Sato, K.; Oba, Y.; Nakamura, H.

CS Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya, 464-8601, Japan

SO Journal of Peptide Research (2004), 64(3), 110-117
CODEN: JPERFA; ISSN: 1397-002X

PB Blackwell Publishing Ltd.

DT Journal

LA English

AB μ-Conotoxin GIIIA, a peptide toxin from the cone snail, blocks muscle-type sodium **channels**. Thr 5 of μ-conotoxin GIIIA, located on the opposite side of the active site in the globular mol., was replaced by Cys to which the bulky tags were attached. The tagged μ-conotoxin GIIIA derivs., except for the phospholipid-tagged one, exerted the biol. activity with a potency slightly weaker than natural μ-conotoxin GIIIA. When the biotinylated tags of various lengths were added, the presence of avidin suppressed the action of the biotinylated toxins of <4 nm, but not with 5 nm. The bulky biotinylated tags are useful as a caliper to measure the depth of receptor sites in the **channels**.

IT **795300-38-8P**
RL: ADV (Adverse effect, including toxicity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(effects of modification at the fifth residue of μ-conotoxin GIIIA with bulky tags on the elec. stimulated contraction of the rat diaphragm)

RN 795300-38-8 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

10458286

AN 2004:566563 CAPLUS
DN 141:123479
TI Preparation of N-aryl benzamides as histone deacetylase inhibitors
IN Schuppan, Detlef; Herold, Christoph; Gansmayer, Marion; Ocker, Matthias; Thierauch, Karl-Heinz
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058234	A2	20040715	WO 2003-EP14071	20031211

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2002-90431 A 20021227
EP 2003-90061 A 20030312
OS MARPAT 141:123479
GI



I



II

AB Histone deacetylase inhibitors I [A = (un)substituted Ph or heterocycle; X = bond, alkyl, alkyloxyalkyl, alkylthioalkyl, etc.; Q = amide, urea, amidoester, etc.; n = 0-4 provided that when X = bond, n is not 0; R1 and R2 independently = H, halo, OH, amino, alkyl, etc.; R3 = OH or amino] and their pharmaceutically acceptable salts are prepared and disclosed as agents to be used in pharmaceutical combinations with phthalazine or pyridazine derivs. (disclosed in prior patent WO 98/35958) which are known angiogenesis inhibitors. Thus, e.g., II was prepared via coupling reaction of 3-pyridinemethanol, N,N'-carbonyldiimidazole and 4-aminomethyl-N-[2-(N-tertbutoxycarbonyl)aminophenyl]benzamide with subsequent removal of N-BOC

group. II was combined with tamoxifen and the VEGF receptor antagonist 1-(4-chloroanilino)-4-(pyridylmethyl)phthalazine hydrochloride and this pharmaceutical composition was evaluated in a colorectal carcinoma model in Wag rats. The results of the model study indicated the combination therapy significantly restricted tumor growth relative to the reference (2 ± 0.5% tumor volume) and the individual application of each compound

IT **722547-82-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of N-arylbenzamides as histone deacetylase inhibitors)

RN 722547-82-2 CAPLUS

CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 16-ethyl-11-methoxy-, (11α,16β,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:513479 CAPLUS

DN 141:71736

TI Isolation and preparation of diterpenoids, compositions thereof, and their use as anticancer or antifungal agents

IN Beauparlant, Pierre; Attardo, Giorgio; Zhang, Zhiying; Stafford, Angela M.; Ubillas, Rosa; Mcalpine, James B.

PA Gemin X Biotechnologies Inc., Can.; Galileo Pharmaceuticals, Inc.; Fortin, Samuel; Tripathy, Sasmita

SO PCT Int. Appl., 185 pp.
CODEN: PIXXD2

DT Patent

LA English

NPA

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004052282	A2	20040624	WO 2003-US38659	20031204
	WO 2004052282	A3	20041007		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-431096P P 20021205

OS MARPAT 141:71736

GI



I



II

AB The present invention relates to diterpenoids I [Q1, Q2 = O, S, NH, NNHR; R = H, C1-10-alkyl, aryl; Q3 = O, S, N(H); R1, R2 = H, halogen, NH2, C1-10-alkyl, C1-10-alkoxy, C1-10-hydroxyalkyl, C1-10-aminoalkyl, C1-10-haloalkyl, , C2-10-alkenyl, C2-10-alkynyl, , C1-10-alkyl, C3-7-cycloalkyl, aryl , C1-10-arylalkyl, 3- to 7-membered heterocycle; CR1R2 = C3-7-cycloalkyl; A = N, CR3; B = N, CR4; D = N, CR5; E = N, CR6 (with the proviso that one of A, B, D, E = CR3, CR4, CR5, CR6); R3, R4, R5, R6 = H, halo, CN, NH2, NO2, CO2H, CONH2, SH, SONH2, SO2NH2, C1-10-oxyalkyl, C1-10-alkyl, C1-10-alkoxy, C1-10-hydroxyalkyl, C1-10-aminoalkyl, C1-10-haloalkyl, C2-10-alkenyl, C2-10-alkynyl, C3-7-cycloalkyl, aryl, C1-10-arylalkyl, 3- to 7-membered non-aromatic heterocycle, 5- to 7-membered aromatic heterocycle, etc.; R3C:CR4, R5C:CR6, R4C:CR5 = C3-7-cycloalkenyl, 5- to 7-membered (non)aromatic heterocycle; R7 = H, C1-10-alkyl, C1-10-alkoxy; R8, R9 = H, halo, CN, NH2, NO2, CO2H, CONH2, SH, SONH2, SO2NH2, C1-10-oxyalkyl, C1-10-alkyl, C1-10-alkoxy, etc.; R10 = H, C1-10-alkyl, C3-7-cycloalkyl, CO-(C1-10-alkyl), C1-10-oxyalkyl, CONH2, CONHR12, aryl; R12 = C1-10-alkyl; halo = F, Cl, Br, I], compns. comprising an effective amount of I, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering an effective amount of I. The compds., compns., and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, or for inducing apoptosis in a cancer or neoplastic cell. The compds., compns., and methods of the invention are further useful for treating or preventing a fungal infection. The compds., compns., and methods of the invention are also useful for inhibiting the growth of a fungus. Podocarpane diterpene II was isolated from Linum arboretum. The effect of II on cancer-cell viability was studied; capases were activated in cancer cell lines H1299 and C33A following 16 h incubation with 1.6μM of I showing selective apoptosis in cancer cells.

IT **709667-53-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and enol silylation of; isolation and preparation of diterpenoids,
compns. thereof, and their use as anticancer or antifungal agents)

RN 709667-53-8 CAPLUS

CN 2(1H)-Phenanthrenone, 3,4,4a,9,10,10a-hexahydro-6-methoxy-1,1,4a-trimethyl-, (4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **709667-52-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oxidation of; isolation and preparation of diterpenoids, compns.
thereof, and their use as anticancer or antifungal agents)
RN 709667-52-7 CAPLUS
CN 2-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-6-methoxy-1,1,4a-trimethyl-, (2S,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **709667-21-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, selenenylation and oxidative deselenation of; isolation and preparation of diterpenoids, compns. thereof, and their use as anticancer or antifungal agents)
RN 709667-21-0 CAPLUS
CN 2(1H)-Phenanthrenone, 3,4,4a,9,10,10a-hexahydro-6-methoxy-1,4a-dimethyl-, (1R,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L14 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:291950 CAPLUS
DN 140:315042

10458286

TI Pin1-modulating compounds and methods of use for the treatment of Pin1-associated diseases, including cancer
IN Mckee, Timothy D.; Suto, Robert K.; Tibbitts, Thomas; Sowadski, Janusz
PA Pintex Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004028535	A1	20040408	WO 2003-US306675	20030303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004214872	A1	20041028	US 2003-379408	20030303
PRAI US 2002-414077P	P	20020926		

OS MARPAT 140:315042
AB The invention is directed to modulators, e.g., inhibitors, of Pin1 and Pin1-related proteins and the use of such modulators for treatment of Pin1 associated states, e.g., for the treatment of cancer. Synthetic methods are included.
IT **676649-27-7**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Pin1-modulating compds. for treatment of Pin1-associated diseases, including cancer)
RN 676649-27-7 CAPLUS
CN 3-Thiazolidinebutanoic acid, 5-[(1,2,3,4,4a,9,10,10a-octahydro-6,7-dimethoxy-3-methyl-2-phenanthrenyl)methylene]-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220882 CAPLUS
DN 141:289239
TI Influence of Estrogen Cytostatics on Activity of Plasma Membrane Enzymes 5'-Nucleotidase and N+-K+-ATPase
AU Mayatskaya, E. E.; Semeikin, A. V.; Rzheznikov, V. M.; Shimanovskii, N. L.
CS Research Center for Endocrinology, Department of Molecular Pharmacology and Radiobiology, Russian State Medical University, USA
SO Bulletin of Experimental Biology and Medicine (Translation of Byulleten

10458286

Eksperimental'noi Biologii i Meditsiny) (2003), 136(6), 557-559
CODEN: BEXBAN; ISSN: 0007-4888
PB Kluwer Academic/Consultants Bureau
DT Journal
LA English
AB The authors studied the effect of four conjugated synthetic derivs. of estrone and ethynylestradiol and bis-β-chloroethylamine-containing substance on activity of plasma membrane enzymes 5'-nucleotidase and N+-K+-ATPase. As differentiated from precursors, estrogen cytostatics decreased activity of plasma membrane enzymes. Reference prepns. chlorophenacyl and estradiol had little effect on activity of 5'-nucleotidase and N+-K+-ATPase. These data suggest that damage to plasma membrane enzymes is related to the effect of estrogen cytostatic mols. Test compds. produced an antiproliferative effect on estrogen-independent tumor cells, which strongly correlated with a decrease in activity of plasma membrane enzymes 5'-nucleotidase and N+-K+-ATPase. The derivative of ethynylestradiol with the cytostatic residue in the 3-position of the steroid nucleus (Po-714-11a) most significantly modulated enzyme activity.
IT **458569-13-6 458569-15-8 762303-31-1 762303-32-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(influence of estrogen cytostatics on activity of plasma membrane enzymes 5'-nucleotidase and N+-K+-ATPase)
RN 458569-13-6 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,11,17-triol, 17-acetate 3-[[4-[bis(2-chloroethyl)amino]phenyl]acetate] 11-formate, (11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 458569-15-8 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,11,17-triol, 11,17-diacetate 3-[[4-[bis(2-chloroethyl)amino]phenyl]acetate], (11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10458286



RN 762303-31-1 CAPLUS
CN 19-Norpregna-1,3,5(10)-trien-20-yne-3,11,17-triol, 17-acetate 3-[4-[bis(2-chloroethyl)amino]benzeneacetate], (11α,17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 762303-32-2 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-[[[4-[bis(2-chloroethyl)amino]phenyl]acetyl]oxy]-11-(formyloxy)-, (11α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220333 CAPLUS
DN 140:270854
TI Preparation of 1,3,8-triazaspiro[4.5]decan-4-ones for the treatment of ORL-1 receptor mediated disorders
IN Battista, Kathleen; Bignan, Gilles; Connolly, Peter J.; Reitz, Allen B.; Morgan Ross, Tina; Scott, Malcolm; Middleton, Steve A.; Orsini, Michael

10458286

PA Janssen Pharmaceutica, N.V., Belg.
SO PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004022558	A2	20040318	WO 2003-US27956	20030905
WO 2004022558	A3	20040521		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004142955	A1	20040722	US 2003-656934	20030905
BR 2003006309	A	20041019	BR 2003-6309	20030905
PRAI US 2002-409134P	P	20020909		
WO 2003-US27956	W	20030905		

OS MARPAT 140:270854
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R0 = CRaRbCOHRa-(CRcRd)1-3X, (CRcRd)1-3COHRaCRaRbX; Ra, Rb = H, alkyl; Rc, Rd = H, OH, carboxy, etc.; X = NR1R2, CONR1R2, NR1, etc.; R1, R2 = H, alkyl, alkoxy, etc.; R3 = aryl, arylalkyl, heteroaryl, etc.; A = (R4)n; R4 = OH, alkyl, alkyl-OH; n = 0-2; B = (L1)m; L1 = alkyl, alkenyl with provisos; m = 0-1; C = (R5)p and (R6)q substituted cycloalkyl, partially unsatd. carbocyclyl (sic), aryl, etc.; R5 = OH, carboxy, halo, etc.; p = 0-5; R6 = (L2)0-1R7; q = 0-1; L2 = alkyl, alkenyl, alkynyl, etc.; R7 = aryl, partially unsatd. carbocyclyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, amination of epoxide II, e.g., prepared from cyclooctanecarboxaldehyde in 2-steps, with 4-aminopyridine afforded amino alc. III. In human ORL-1 receptor binding affinity assays, approx. 470-examples of compds. I exhibited IC50 values ranging from 0.10 - >10,000 nM, e.g., the IC50 value of triazaspiro[4.5]decan-4-one III was 8.73 nM. Compds. I are claimed useful for the treatment of anxiety, depression, migraine, etc..

IT **674789-13-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug target; preparation of triazaspiro[4.5]decan-4-ones for the treatment of ORL-1 receptor mediated disorders)

RN 674789-13-0 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decan-4-one, 3-[(2S)-2-hydroxy-3-[[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]amino]propyl]-1-phenyl-8-[2-[2-(2-thienyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **674478-64-9P 674789-14-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazaspiro[4.5]decan-4-ones for the treatment of ORL-1 receptor mediated disorders)

RN 674478-64-9 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-cyclooctyl-1-(4-fluorophenyl)-3-[(2R)-2-hydroxy-3-[[[(1S,4aR,10aS)-1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 674789-14-1 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-(1,2-dihydro-1-acenaphthylenyl)-1-(4-fluorophenyl)-3-[(2S)-2-hydroxy-3-[[[(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a-

octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenyl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:182541 CAPLUS
DN 140:229476
TI Treatment of dyspareunia with topically administered nitroglycerin formulations
IN Place, Virgil A.; Wilson, Leland F.; Doherty, Paul C.; Hanamoto, Mark S.; Spivack, Alfred P.; Gesundheit, Neil; Bennett, Sean R.; Doherty, Jane K.
PA USA
SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 905,458.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004044080	A1	20040304	US 2003-407858	20030404
	US 5877216	A	19990302	US 1997-959064	19971028
	US 6306841	B1	20011023	US 2000-539484	20000330
	US 2001051656	A1	20011213	US 2001-905458	20010713
	US 6593313	B2	20030715		
PRAI	US 1997-959057	B2	19971028		
	US 1997-959064	A2	19971028		
	US 1998-181316	B1	19981027		
	US 2000-539484	A1	20000330		
	US 2001-905458	A2	20010713		

AB Methods and formulations for treating dyspareunia are provided. A pharmaceutical composition formulated so as to contain a therapeutically effective amount of nitroglycerin is administered to the vagina or vulvar area of the individual undergoing treatment. Preferred formulations are immediate release formulations in which at least 80% of the nitroglycerin in the formulation is released therefrom within 4 h following administration. The formulations may contain one or more addnl. active agents, e.g., agents that are also useful to treat dyspareunia and/or potentiate the action of nitroglycerin. Such addnl. agents include vasoactive agents such as prostaglandins, phosphodiesterase inhibitors, androgens such as testosterone, estrogens such as estradiol, and selective modulators of estrogen and androgen receptors. A kit for a patient to use in the self-administration of the formulation is also provided.

10458286

IT **666702-84-7**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective estrogen receptor modulator, as addnl. active agent; dyspareunia treatment with topically administered nitroglycerin formulations)
RN 666702-84-7 CAPLUS
CN Estra-1,3,5(10)-triene-7-undecanamide, N-butyl-3,17-dihydroxy-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:828852 CAPLUS
DN 140:139694
TI The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-α on endothelial and fibroblast cell growth, morphology and apoptosis
AU Ho, Y. T.; Newman, S. P.; Purohit, A.; Leese, M. P.; Potter, B. V. L.; Reed, M. J.
CS Faculty of Medicine, Endocrinology and Metabolic Medicine and Sterix Ltd., Imperial College, St. Mary's Hospital, London, W2 1NY, UK
SO Journal of Steroid Biochemistry and Molecular Biology (2003), 86(2), 189-196
CODEN: JSBBEZ; ISSN: 0960-0760
PB : Elsevier Science Ltd.
DT Journal
LA English
AB 2-Methoxyoestradiol (2-MeOE2) is a potent anti-angiogenic agent. Its 3- and 17-sulfamoylated derivs. have been demonstrated to induce G2-M cell cycle arrest and apoptosis in breast cancer cells in vitro as well as tumor regression in rats in vivo with greater potency than the parent estrogen. To determine whether the anti-cancer properties of these derivs. can be synergistically enhanced with low-dose TNF-α co-treatment, the authors investigated the effects of these treatments in adult human fibroblasts and human umbilical vein endothelial cells (HUVECs). Treatment of fibroblasts with 0.1 μM 2-methoxyoestradiol-3,17-bis sulfamate (2-MeOE2bisMATE) but not 2-MeOE2 caused a reversible morphol. change and induced G2-M arrest (from 12 to 33%) but not subsequent apoptosis. In contrast, treatment of HUVECs did not induce morphol. change or G2-M arrest. Using a nucleosomal ELISA assay, the authors showed that TNF-α (20 ng/mL) combination treatment synergistically increases 0.1 μM 2-MeOE2bisMATE-induced but not 0.1 μM 2-MeOE2-induced apoptosis in HUVECs. These results suggest that TNF-α co-treatment may be a beneficial method of increasing the potency of 2-substituted estrogens as anti-angiogenic agents through synergistic induction of apoptosis in endothelial cells while maintaining

low cytotoxicity to fibroblasts.

IT **401600-86-0**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effects of 2-methoxy estrogens and their sulfamoylated derivs. in conjunction with TNF-α on human vascular endothelial and dermal fibroblast cell growth, morphol. and apoptosis)

RN 401600-86-0 CAPLUS

CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-, disulfamate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:719252 CAPLUS

DN 139:224972

TI Synthesis of 2-methoxyestradiol derivatives and uses as antiangiogenic agents

IN Lavallee, Theresa M.; Pribluda, Victor S.; Simons, Jonathan; Mabjeesh, Nicola; Giannakakou, Paraskevi

PA Entremed, Inc., USA

SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2

DT Patent

LA English

NPA

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003073985	A2	20030912	WO 2003-US5898	20030227
WO 2003073985	A3	20031231		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-361267P P 20020301

AB Compns. and methods for treating mammalian disease characterized by undesirable angiogenesis and for controlling a number of angiogenesis-related events, conditions, or substances, by administering derivs. of

2-methoxyestradiol of general formula (I) wherein the variables are defined in the specification.

IT **431901-79-0 431901-81-4 431901-84-7 431901-85-8 431901-89-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of 2-methoxyestradiol derivs. and uses as antiangiogenic agents)

RN 431901-79-0 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 16-(2-butenyl)-2-methoxy-3-(phenylmethoxy)-, (16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 431901-81-4 CAPLUS
CN Estra-1,3,5(10)-triene-16-carboxylic acid, 2-methoxy-17-oxo-3-(phenylmethoxy)-16-(2-propenyl)-, methyl ester, (16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-84-7 CAPLUS
CN Estra-1,3,5(10)-triene-16-carboxylic acid, 2-methoxy-17-oxo-3-(phenylmethoxy)-, methyl ester, (16β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10458286

RN 431901-85-8 CAPLUS
CN Estra-1,3,5(10)-trien-17-ol, 16-(2-butenyl)-2-methoxy-3-(phenylmethoxy)-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 431901-89-2 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **431901-68-7P 431901-69-8P 431901-70-1P**
431901-71-2P 431901-72-3P 431901-77-8P
431901-78-9P 431901-80-3DP, alkyl derivs.
431901-89-2DP, alkyl analogs **431901-90-5P**
431901-91-6P 431901-92-7P 431901-93-8P
431901-98-3P 431901-99-4P 431902-01-1P
431902-02-2P 431902-03-3P 431902-04-4P
431902-05-5P 431902-06-6P 438044-30-5P
464924-32-1P 594873-85-5P 594873-86-6P
594873-87-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 2-methoxyestradiol derivs. and uses as antiangiogenic agents)
RN 431901-68-7 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 17-amino-2-methoxy-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-69-8 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-methoxy-, oxime (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 431901-70-1 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 2-methoxy-17-propyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-71-2 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 2-methoxy-17-methyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-72-3 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 2-methoxy-17-propylidene-, (17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 431901-77-8 CAPLUS
CN 19,21-Dinorchola-1,3,5(10),17(20)-tetraen-3-ol, 2-methoxy-, (17Z)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 431901-78-9 CAPLUS
CN 19,21-Dinorchola-1,3,5(10)-trien-3-ol, 2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-80-3 CAPLUS
CN Estra-1,3,5(10)-triene-16-carboxylic acid, 2-methoxy-17-oxo-3-(phenylmethoxy)-, methyl ester, (16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-89-2 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-90-5 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 2-(dimethylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10458286

RN 431901-91-6 CAPLUS
CN Formamide, N-(3-hydroxyestra-1,3,5(10)-trien-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-92-7 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 2-(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-93-8 CAPLUS
CN Estra-1,3,5(10)-trien-3-ol, 2-azido- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-98-3 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-99-4 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-01-1 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-(hydroxymethyl)-2-methoxy-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-02-2 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-(hydroxymethyl)-2-methoxy-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10458286



RN 431902-03-3 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-propyl-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-04-4 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-propyl-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-05-5 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-butyl-2-methoxy-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10458286



RN 431902-06-6 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-(2-methylpropyl)-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438044-30-5 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-[(dimethylamino)methyl]-2-methoxy-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 464924-32-1 CAPLUS
CN Estra-1,3,5(10)-triene-16-methanol, 17-hydroxy-2-methoxy-3-(phenylmethoxy)-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 594873-85-5 CAPLUS
CN Estra-1,3,5(10)-trien-17-ol, 16-[(dimethylamino)methyl]-2-methoxy-3-(phenylmethoxy)-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 594873-86-6 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 594873-87-7 CAPLUS
CN 19-Norpregna-1,3,5(10),17(20)-tetraen-3-ol, 2-methoxy-, (17E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



NPA

L14 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:610198 CAPLUS
DN 139:159968
TI Nonsteroidal analogs of 2-methoxyestradiol for the treatment of diseases characterized by undesirable angiogenesis, proliferative activity, or cell mitosis
IN Agoston, Gregory; Shah, Jamshed H.; Hunsucker, Kimberly A.; Treston, Anthony M.; Pribluda, Victor S.
PA Entremed, Inc., USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063787	A2	20030807	WO 2003-US2728	20030130
	WO 2003063787	A3	20040122		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003187076	A1	20031002	US 2003-354921	20030130
	US 2003236439	A1	20031225	US 2003-354927	20030130
PRAI	US 2002-354046P	P	20020130		

OS MARPAT 139:159968
GI



I



II



III

AB The invention provides compds., compns., and methods for treating disease states characterized by undesirable angiogenesis, proliferative activity, or cell mitosis by administering 2-methoxyestradiol nonsteroidal analogs I, II or III [R1 = (substituted) alkyl, (substituted) aryl; R2, R3 = H, halo, (substituted) alkyl, etc.]. Preparation of e.g. I (R1, R2 = Me; R3 = H) is described.

IT **573976-95-1D**, derivs. **573979-27-8 573979-28-9**
573979-29-0 573979-30-3 573979-35-8
573979-36-9 573979-37-0 573979-38-1
573979-39-2 573979-40-5 573979-41-6
573979-42-7 573979-43-8 573979-44-9
573979-45-0 573979-46-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methoxyestradiol nonsteroidal analogs for treatment of diseases characterized by undesirable angiogenesis, proliferative activity, or cell mitosis)

RN 573976-95-1 CAPLUS

CN 2,3-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro- (9CI) (CA INDEX NAME)



RN 573979-27-8 CAPLUS

CN 2-Phenanthrenol, 8-ethyl-4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7,7-dimethyl- (9CI) (CA INDEX NAME)



RN 573979-28-9 CAPLUS
CN 2-Phenanthrenemethanol, 1-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-6-methoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 573979-29-0 CAPLUS
CN 2-Phenanthrenol, 7-ethenyl-8-ethyl-4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7-methyl- (9CI) (CA INDEX NAME)



RN 573979-30-3 CAPLUS
CN 2-Phenanthrenol, 8-ethyl-4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7-methyl-7-(1-propenyl)- (9CI) (CA INDEX NAME)



RN 573979-35-8 CAPLUS
CN 2-Phenanthrenol, 7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7,8-dimethyl- (9CI) (CA INDEX NAME)



RN 573979-36-9 CAPLUS
CN 2-Phenanthrenemethanol, 1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-6-methoxy-α,1,2-trimethyl- (9CI) (CA INDEX NAME)



RN 573979-37-0 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7,8-dimethyl-7-(1-methylethenyl)- (9CI) (CA INDEX NAME)



RN 573979-38-1 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7,8-dimethyl-7-(1-methyl-1-propenyl)- (9CI) (CA INDEX NAME)



RN 573979-39-2 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7-methyl-8-propyl- (9CI) (CA INDEX NAME)



RN 573979-40-5 CAPLUS
CN 1-Phenanthrenepropanol, 1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-6-methoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 573979-41-6 CAPLUS
CN 2-Phenanthrenol, 8-(3-butenyl)-4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7-methyl- (9CI) (CA INDEX NAME)



RN 573979-42-7 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7-methyl-8-(3-pentenyl)- (9CI) (CA INDEX NAME)



RN 573979-43-8 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7-methyl-7-propyl- (9CI) (CA INDEX NAME)



RN 573979-44-9 CAPLUS
CN 2-Phenanthrenemethanol, α-ethyl-1,2,3,4,4a,9,10,10a-octahydro-7-hydroxy-6-methoxy-1,2-dimethyl- (9CI) (CA INDEX NAME)



RN 573979-45-0 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7,8-dimethyl-7-(1-methylenepropyl)- (9CI) (CA INDEX NAME)



RN 573979-46-1 CAPLUS
CN 2-Phenanthrenol, 7-(1-ethyl-1-propenyl)-4b,5,6,7,8,8a,9,10-octahydro-3-methoxy-7,8-dimethyl- (9CI) (CA INDEX NAME)



L14 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:252155 CAPLUS
DN 139:78657
TI Novel 2-methoxyestradiol analogues with antitumor activity
AU Tinley, Tina L.; Leal, Rachel M.; Randall-Hlubek, Deborah A.; Cessac,

10458286

James W.; Wilkens, Lynne R.; Rao, Pemmaraju N.; Mooberry, Susan L.

CS Departments of Physiology and Medicine, Southwest Foundation for Biomedical Research, San Antonio, TX, 78227, USA

SO Cancer Research (2003), 63(7), 1538-1549
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English

AB 2-Methoxyestradiol (2-ME2) is a natural estrogen metabolite that, while devoid of estrogenic effects, has both antiangiogenic and antitumor effects. 2-ME2 is currently being evaluated in Phase I and Phase II clin. trials for the treatment of multiple types of cancer. Novel analogs of 2-ME2 were tested for activities that predict antiangiogenic and antitumor effects. Selected analogs were tested for inhibitory activity against endothelial cell proliferation and invasion. The results show that these analogs are effective inhibitors of endothelial cell activities that may predict antiangiogenic activity, and one analog, 2-methoxy-14-dehydroestradiol (14-dehydro-2-ME2), was 6-15-fold more potent than the parental compound in these assays. The analogs were also evaluated for inhibition of proliferation and cytotoxicity against multiple tumor cell lines and found to be potent and effective. 14-Dehydro-2-ME2 was approx. 15-fold more potent than 2-ME2 against various tumor cell lines, and 2-methoxy-15-dehydroestradiol was particularly effective against DU 145 and PC3 prostate cancer cell lines. In vivo antitumor activity was observed for the three analogs tested in the murine xenograft MDA-MB-435 model; however, 2-ME2 provided no antitumor activity in this trial. The two most effective analogs, 14-dehydro-2-ME2 and 2-methoxyestradiol-15α,16α-acetonide, provided 29.4% and 26.7% inhibition of tumor burden, resp. Mechanism of action studies indicate that the analogs cause mitotic spindle disruption, mitotic arrest, microtubule depolymn., and inhibition of the assembly of purified tubulin similar to the effects of 2-ME2. Consistent with antimitotics that inhibit the dynamic instability of tubulin and initiate apoptosis, these novel 2-ME2 analogs cause Bcl-2 phosphorylation and activation of mitogen-activated protein kinase signaling pathways.

IT **477951-76-1 477951-83-0**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel 2-methoxyestradiol analogs with antitumor activity in relation to signal transduction and mechanism of action)

RN 477951-76-1 CAPLUS
CN Estra-1,3,5(10),15-tetraene-3,17-diol, 2-methoxy-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-83-0 CAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, 2-methoxy-, cyclic 15,16-(1-methylethylidene acetal), (15α,16α,17β)- (9CI) (CA INDEX NAME)

10458286

Absolute stereochemistry.



RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:153417 CAPLUS
DN 138:187528
TI Preparation of octahydrophenanthrenes as NMDA antagonists
IN Buschmann, Helmut Heinrich; Englberger, Werner Guenter; Przewosny, Michael; Sattlegger, Michael; Schick, Hans; Henkel, Birgitta
PA Gruenenthal GmbH, Germany
SO Ger. Offen., 14 pp.
CODEN: GWXXBX
DT Patent
LA German

NPA

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10140213	A1	20030227	DE 2001-10140213	20010816
	WO 2003016261	A1	20030227	WO 2002-EP8866	20020808
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1423353	A1	20040602	EP 2002-794708	20020808
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	US 2004162432	A1	20040819	US 2004-778380	20040213
PRAI	DE 2001-10140213	A	20010816		
	WO 2002-EP8866	W	20020808		

OS CASREACT 138:187528; MARPAT 138:187528
GI



I

AB Title compds. [I; R, R1, R2 = H, (branched) (saturated) acyclic group, (saturated) cyclic group, alkylenearyl, alkyleneheteroaryl, halo, cyano, OR5, SR5, CHF2, CF3, NHR5, N(R5)2, NO2, SO2R5; R2 = oxo group; R3, R4 = H, (branched) (saturated) acyclic group, (saturated) cyclic group, alkylenearyl, alkyleneheteroaryl; or R3R4 = (CH2)2-7; R5 = (branched) (saturated) C1-12 acyclic group, C3-7 cyclic group, (hetero)aryl] and racemates, diastereoisomers or enantiomers thereof were prepared Thus, N,N-dimethyl-N-[(1R, 4aS,10aS)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-ylmethyl]amine (preparation given) in MeCOEt was stirred with ClSiMe3 for 4.5 h at room temperature to give 66% N,N-dimethyl-N-[(1R, 4aS,10aS)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-ylmethyl]amine hydrochloride. The latter at 10 μM gave 46% inhibition of (3H)-(+)-MK801 binding, and at 10 mg/kg i.v. in mice 74% inhibition of phenylquinone-induced writhing.

IT **498546-57-9P 498546-64-8P 498546-68-2P 498546-75-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of octahydrophenanthrenes as NMDA antagonists)

RN 498546-57-9 CAPLUS
CN 1-Phenanthrenemethanamine, 1,2,3,4,4a,9,10,10a-octahydro-N,N-dimethyl-, hydrochloride, (1R,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 498546-64-8 CAPLUS
CN 1-Phenanthrenemethanamine, 1,2,3,4,4a,9,10,10a-octahydro-6-methoxy-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 498546-68-2 CAPLUS
CN 3-Phenanthrenol, 8-[(dimethylamino)methyl]-4b,5,6,7,8,8a,9,10-octahydro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 498546-75-1 CAPLUS
CN 1-Phenanthrenemethanamine, 3-(1,1-dimethylethyl)-1,2,3,4,4a,9,10,10a-octahydro-N,N-dimethyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **498546-53-5P 498546-62-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of octahydrophenanthrenes as NMDA antagonists)
RN 498546-53-5 CAPLUS
CN 1-Phenanthrenemethanamine, 1,2,3,4,4a,9,10,10a-octahydro-N,N-dimethyl-, (1R,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10458286



RN 498546-62-6 CAPLUS
CN 1-Phenanthrenemethanamine, 1,2,3,4,4a,9,10,10a-octahydro-6-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:22633 CAPLUS
DN 138:67085
TI Preparation of activators of non-genotropic estrogen-like signaling (ANGELS) for use in stimulating bone formation and treating other diseases
IN Manolagas, Stavros C.; Katzenellenbogen, John A.
PA Anabonix, Inc., USA; The Board of Trustees of the University of Arkansas
SO PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003002058	A2	20030109	WO 2002-US18544	20020610
	WO 2003002058	C1	20030327		
	WO 2003002058	A3	20030828		
	WO 2003002058	C2	20040708		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003119800	A1	20030626	US 2002-165380	20020607
	EP 1404344	A2	20040407	EP 2002-749579	20020610
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-299009P	P	20010618		
	US 2002-165380	A	20020607		
	WO 2002-US18544	W	20020610		

OS MARPAT 138:67085
AB The inventors have discovered compds. that are Activators of

10458286

Non-Genotropic Estrogen-like Signaling (ANGELS). ANGELS compds. are small mols. that mimic the non-genotropic effects of estrogen and androgen but substantially lack their genotropic effects. For example, the inventors have discovered that ANGELS compds. stimulate the formation of bone but have little or no feminizing or masculinizing effects. In preferred embodiments, the ANGELS are an estrenediol, androstenediol, estranediol, androstanediol, nor-estrenediol, homo-estrenediol, seco-estrenediol, nor-androstenediol, homo-androstenediol, seco-androstenediol, nor-estranediol, homo-estranediol, seco-estranediol, nor-androstanediol, homo-androstanediol, seco-androstanediol, or a estratrienol. Pharmaceutical compns. containing the ANGELS are addnl. claimed.

IT **481695-81-2DP**, Estra-1,3,5(10)-trien-4-ol, analogs
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of activators of non-genotropic estrogen-like signaling (ANGELS) for use in stimulating bone formation and treating other diseases)

RN 481695-81-2 CAPLUS
CN Estra-1,3,5(10)-trien-4-ol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:964373 CAPLUS
DN 138:24877
TI Preparation of novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
IN Rao, Pemmaraju Narasimha; Mooberry, Susan L.; Cessac, James W.; Tinley, Tina L.
PA Southwest Foundation for Biomedical Research, USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002100877	A1	20021219	WO 2002-US18867	20020611

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

10458286

	US 2003096799	A1	20030522	US 2002-167208	20020611
	US 6593321	B2	20030715		
	US 2003229061	A1	20031211	US 2003-412007	20030411
PRAI	US 2001-297428P	P	20010611		
	US 2002-167208	A3	20020611		

OS MARPAT 138:24877

GI



I



II

AB Novel 2-alkoxyestradiol analogs of formula I [R1 = alkyl, haloalkyl; R2 = H, SO2NHR; R = H, alkyl, acyl; R3 = H, alkyl, haloalkyl; R4 = H, alkyl, alkenyl, alkynyl, aryl, heteroaryl; R5 = alkyl; R6 = O, NOR, OSO2NHR] are prepared which inhibit undesired cell proliferation and tumor growth. Addnl., methods are disclosed of treating diseases associated with undesired angiogenesis and undesired proliferation, and methods of treating infectious disease wherein the infectious agent is particularly susceptible to inhibition by agents that disrupt microtubule organization and function. Thus, II was prepared from estradiol in several steps. II was 6-24 times more potent than 2-methoxyestradiol in 5 human tumor cell lines.

IT **477951-76-1P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of alkoxyestradiol analogs with antiproliferative and antimitotic activity)

RN 477951-76-1 CAPLUS

CN Estra-1,3,5(10),15-tetraene-3,17-diol, 2-methoxy-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477951-83-0P 477951-84-1P 477951-90-9P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of alkoxyestradiol analogs with antiproliferative and antimitotic activity)

RN 477951-83-0 CAPLUS

10458286

CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, 2-methoxy-, cyclic 15,16-(1-methylethylidene acetal), (15α,16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-84-1 CAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, 2-methoxy-, cyclic 15,16-(1-methylethylidene acetal), (15β,16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-90-9 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-7-methyl-, (7α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **477951-70-5P 477951-71-6P 477951-72-7P 477951-73-8P 477951-74-9P 477951-75-0P 477951-79-4P 477951-80-7P 477951-81-8P 477951-82-9P 477951-85-2P 477951-86-3P 477951-87-4P 477951-88-5P 477951-89-6P 477951-91-0P 477951-92-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of alkoxyestradiol analogs with antiproliferative and antimitotic activity)

RN 477951-70-5 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 2-methoxy-3-(phenylmethoxy)-, cyclic 1,2-ethanediyl acetal (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-71-6 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-hydroxy-2-methoxy-, cyclic 1,2-ethanediyl acetal (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-72-7 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-(acetyloxy)-2-methoxy-, cyclic 17-(1,2-ethanediyl acetal) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-73-8 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-(acetyloxy)-16-bromo-2-methoxy-, cyclic

17-(1,2-ethanediyl acetal), (16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-74-9 CAPLUS
CN Estra-1,3,5(10),15-tetraen-17-one, 3-(acetyloxy)-2-methoxy-, cyclic 17-(1,2-ethanediyl acetal) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-75-0 CAPLUS
CN Estra-1,3,5(10),15-tetraen-17-one, 3-hydroxy-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-79-4 CAPLUS
CN Estra-1,3,5(10),15-tetraene-3,17-diol, 2-methoxy-, diacetate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-80-7 CAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, 2-methoxy-, 3,17-diacetate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-81-8 CAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, 2-methoxy-, tetraacetate, (15α,16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-82-9 CAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, 2-methoxy-, (15α,16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-85-2 CAPLUS
CN Ethanone, 1-[(7α,17β)-17-(acetyloxy)-3-hydroxy-7-methylestra-1,3,5(10)-trien-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-86-3 CAPLUS
CN Ethanone, 1-[(7α,17β)-17-(acetyloxy)-7-methyl-3-(phenylmethoxy)estra-1,3,5(10)-trien-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-87-4 CAPLUS
CN Estra-1,3,5(10)-triene-2,17-diol, 7-methyl-3-(phenylmethoxy)-, diacetate, (7α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-88-5 CAPLUS
CN Estra-1,3,5(10)-triene-2,17-diol, 7-methyl-3-(phenylmethoxy)-, (7α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-89-6 CAPLUS
CN Estra-1,3,5(10)-trien-17-ol, 2-methoxy-7-methyl-3-(phenylmethoxy)-, (7α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477951-91-0 CAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, 2-methoxy-, tetraacetate, (15β,16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10458286



RN 477951-92-1 CAPLUS
CN Estra-1,3,5(10)-triene-3,15,16,17-tetrol, 2-methoxy-, (15β,16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:778714 CAPLUS
DN 137:279370
TI Preparation of 2-methoxyestradiol derivatives as antiangiogenic agents
IN Agoston, Gregory E.; Pribluda, Victor; Treston, Anthony M.; Green, Shawn J.
PA USA
SO U.S. Pat. Appl. Publ., 15 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002147183	A1	20021010	US 2001-779331	20010208
PRAI US 2001-779331		20010208		

OS CASREACT 137:279370; MARPAT 137:279370
GI



I



II

AB Derivs. of 2-methoxyestradiol of formula I [R1, R4 = H, halo, CN, alkyl, OH, CH2OH, NH2, etc.; R2 = N3, CN, alkynyl, alkenyl, alkoxy, etc.; R3 = H, OH, hydroxyalkyl, etc.; R5 = H, oxo, OH, NOH, etc.; R6, R7 = H, alkyl, alkenyl, alkynyl, etc.; R8 = OH, oxo, NOH, etc.] are prepared for the treatment of mammalian disease characterized by undesirable angiogenesis. Thus, II was prepared from 2-methoxyestradiol, and had IC50 of <0.5 μM against MDA-MB-231 human breast carcinoma cells.

IT **431901-87-0P 431901-98-3P 431901-99-4P**
431902-00-0P 431902-01-1P 431902-02-2P
431902-03-3P 431902-04-4P 431902-05-5P
431902-06-6P 438044-30-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-methoxyestradiol derivs. as antiangiogenic agents)

RN 431901-87-0 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-butyl-2-methoxy-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-98-3 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10458286

RN 431901-99-4 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-methyl-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-00-0 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-ethyl-2-methoxy-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-01-1 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-(hydroxymethyl)-2-methoxy-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-02-2 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-(hydroxymethyl)-2-methoxy-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-03-3 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-propyl-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-04-4 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-propyl-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-05-5 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-butyl-2-methoxy-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431902-06-6 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 2-methoxy-16-(2-methylpropyl)-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 438044-30-5 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-[(dimethylamino)methyl]-2-methoxy-, (16β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **431901-79-0P 431901-82-5P 431901-85-8P**
464924-28-5P 464924-29-6P 464924-30-9P
464924-31-0P 464924-32-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-methoxyestradiol derivs. as antiangiogenic agents)
RN 431901-79-0 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 16-(2-butenyl)-2-methoxy-3-(phenylmethoxy)-, (16α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 431901-82-5 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 2-methoxy-3-(phenylmethoxy)-16-(2-propenyl)-, (16β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 431901-85-8 CAPLUS
CN Estra-1,3,5(10)-trien-17-ol, 16-(2-butenyl)-2-methoxy-3-(phenylmethoxy)-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 464924-28-5 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 16-(2-butenyl)-2-methoxy-3-(phenylmethoxy)-, (16β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 464924-29-6 CAPLUS
CN Estra-1,3,5(10)-triene-16-carboxylic acid, 2-methoxy-17-oxo-3-(phenylmethoxy)-16-(2-propenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 464924-30-9 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 16-[(dimethylamino)methyl]-2-methoxy-3-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 464924-31-0 CAPLUS
CN Estra-1,3,5(10)-triene-16-carboxylic acid, 2-methoxy-17-oxo-3-(phenylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10458286



RN 464924-32-1 CAPLUS
CN Estra-1,3,5(10)-triene-16-methanol, 17-hydroxy-2-methoxy-3-(phenylmethoxy)-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:521687 CAPLUS
DN 137:93613
TI Preparation of phenanthrenes for therapeutic use as estrogen receptor ligands
IN Koehler, Konrad; Henssen, Cecilia; Nilsson, Marita; Gillner, Mikael; Liu, Ye; Sanin, Andrei; Wilkening, Robert R.; Ratcliffe, Ronald W.
PA Karo Bio A.B., Swed.; Merck & Co., Inc.; et al.
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002053522	A2	20020711	WO 2001-EP15230	20011224
	WO 2002053522	A3	20040108		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2433828	AA	20020711	CA 2001-2433828	20011224
	EP 1399406	A2	20040324	EP 2001-272663	20011224
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

10458286

	JP 2004523508	T2	20040805	JP 2002-554641	20011224
	US 2004127576	A1	20040701	US 2004-250521	20040120
PRAI	GB 2001-163	A	20010104		
	GB 2001-164	A	20010104		
	GB 2001-6434	A	20010315		
	WO 2001-EP15230	W	20011224		

OS MARPAT 137:93613

GI



I



II

AB Phenanthrenes, such as I [R1 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl; R1 ≠ Ph; R1, R3 = oxo, thioxo, H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl; R4, R10a = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl; R4a = H, Me, Et, etc.; 1,10-, 1,2-, 2,3-saturated or -unsatd.], were prepared for pharmaceutical use as estrogen receptor modulators for the treatment or prevention of a variety of conditions related to estrogen functioning including bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, autoimmune disease, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer of the lung, colon, breast, uterus, and prostate. Thus, phenanthrenone II was prepd in five steps starting from MeO-3-C6H4I. The prepared phenanthrenes were assayed for estrogen receptor binding activity with binding affinities for the α- and β-subtypes in the range of IC50 3 to 10,000 nM. Pharmaceutical compns. of the phenanthrenes were also presented.

IT **441330-80-9P 441330-85-4P 441330-86-5P**
441330-89-8P 441330-90-1P 441330-94-5P
441330-95-6P 441330-99-0P 441331-01-7P
441331-03-9P 441331-11-9P 441331-13-1P
441331-18-6P 441331-20-0P 441331-26-6P
441331-36-8P 441331-38-0P 441331-71-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of phenanthrenes for therapeutic use as selective estrogen receptor modulators)

RN 441330-80-9 CAPLUS

CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-85-4 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-86-5 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-, (1R,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-89-8 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-90-1 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1'-butyl-1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-94-5 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-2-methyl-, (1R,2S,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-95-6 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-2-methyl-, (1R,2R,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-99-0 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-1-(3-methylbutyl)-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-01-7 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-1-(2-phenylethyl)-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-03-9 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-2,10a-dimethyl-1-(3-methylbutyl)-, (1R,2S,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-11-9 CAPLUS
CN 3(2H)-Phenanthrenone, 10a-ethyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-13-1 CAPLUS
CN 3(2H)-Phenanthrenone, 10a-ethyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-1-(3-methylbutyl)-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-18-6 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-4-phenyl-, (4R,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-20-0 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-1'-(2-phenylethyl)-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-26-6 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-1-(3-methylbutyl)-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-36-8 CAPLUS
CN Spiro[cyclobutane-1,3'(2'H)-phenanthren]-2-one, 1',4',4'a,9',10',10'a-hexahydro-7'-hydroxy-10'a-methyl-, (1R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10458286



RN 441331-38-0 CAPLUS
CN Dispiro[1,3-dithiolane-2,1'-cyclobutane-2',3''(2''H)-phenanthren]-7''-ol, 1'',4'',4''a,9'',10'',10''a-hexahydro-10''a-methyl-, (2'R,4''aR,10''aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-71-1 CAPLUS
CN 2(1H)-Phenanthrenone, 3,4,4a,9,10,10a-hexahydro-7-hydroxy-4a-methyl-, (4aR,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **441330-81-0P 441330-87-6P 441330-88-7P**
441330-91-2P 441330-96-7P 441330-97-8P
441330-98-9P 441331-00-6P 441331-02-8P
441331-04-0P 441331-05-1P 441331-06-2P
441331-07-3P 441331-08-4P 441331-09-5P
441331-10-8P 441331-12-0P 441331-14-2P
441331-15-3P 441331-16-4P 441331-17-5P
441331-19-7P 441331-21-1P 441331-22-2P
441331-23-3P 441331-24-4P 441331-25-5P
441331-27-7P 441331-28-8P 441331-29-9P
441331-30-2P 441331-31-3P 441331-32-4P
441331-33-5P 441331-34-6P 441331-35-7P

441331-37-9P 441331-39-1P 441331-41-5P
441331-42-6P 441331-43-7P 441331-44-8P
441331-45-9P 441331-46-0P 441331-48-2P
441331-49-3P 441331-55-1P 441331-62-0P
441331-65-3P 441331-66-4P 441331-69-7P
441331-70-0P 441331-72-2P 441331-73-3P
441331-74-4P 441331-75-5P 441331-76-6P
441348-21-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenanthrenes for therapeutic use as selective estrogen receptor modulators)

RN 441330-81-0 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-, (4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-87-6 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1'-butyl-1',4',4'a,9',10',10'a-hexahydro-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-88-7 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1'-butyl-1',4',4'a,9',10',10'a-hexahydro-, (1'R,4'aS,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-91-2 CAPLUS
CN 2-Phenanthrenol, 8-butyl-4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-, (4bR,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-96-7 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-4-methyl-, (1R,4S,4aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-97-8 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1'-butyl-1',4',4'a,9',10',10'a-hexahydro-2'-methyl-, (1'R,2'R,4'aS,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441330-98-9 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1'-butyl-1',4',4'a,9',10',10'a-hexahydro-2'-methyl-, (1'R,2'S,4'aS,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-00-6 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-1'-(3-methylbutyl)-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-02-8 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-2,10a-dimethyl-1-(3-methylbutyl)-, (1R,2R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-04-0 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-6,6-dimethoxy-8a-methyl-8-(3-methylbutyl)-, (4bR,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-05-1 CAPLUS
CN Spiro[1,3-dioxolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-1'-(3-methylbutyl)-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-06-2 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-8-(3-methylbutyl)-, (4bR,8S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-07-3 CAPLUS
CN 2-Phenanthrenol, 6-(ethylthio)-4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-8-(3-methylbutyl)-, (4bR,6S,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-08-4 CAPLUS
CN Spiro[1,3-dithiane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-1'-(3-methylbutyl)-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-09-5 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-10-8 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-, (4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-12-0 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 10'a-ethyl-1',4',4'a,9',10',10'a-hexahydro-, (4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-14-2 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-1-(3-methylbutyl)-, (1S,4aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441331-15-3 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-1-(3-methylbutyl)-, (1R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441331-16-4 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 10'a-ethyl-1',4',4'a,9',10',10'a-hexahydro-1'-(3-methylbutyl)-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-17-5 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-4a,10a-dimethyl-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-19-7 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-4'-phenyl-, (4'R,4'aS,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-21-1 CAPLUS
CN Spiro[1,3-dioxolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-, (4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-22-2 CAPLUS
CN Spiro[1,3-dioxolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-, (4'aR,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-23-3 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-pentyl-, (4bR,6R,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-24-4 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-pentyl-, (4bR,6S,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-25-5 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-2',10'a-dimethyl-1'-(3-methylbutyl)-, (1'R,2'S,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-27-7 CAPLUS
CN Spiro[1,3-dithiane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-, (4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-28-8 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-hydroxy-4,10a-dimethyl-, (1R,4R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-29-9 CAPLUS
CN Spiro[1,3-dithiolane-2,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-4',10'a-dimethyl-, (4'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-30-2 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-4-(phenylmethyl)-, (4R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-31-3 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-4,4-bis(phenylmethyl)-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-32-4 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-methylene-, (4bR,8aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-33-5 CAPLUS
CN Spiro[cyclopropane-1,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-, (4'aR,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-34-6 CAPLUS
CN Spiro[2,4-cyclohexadiene-1,3'(2'H)-phenanthren]-7'-ol, 2,3,4,5-tetrachloro-1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-, (1R,4'aS,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-35-7 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-[1-(phenylthio)cyclopropyl]-, (4bR,6R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-37-9 CAPLUS
CN Spiro[cyclobutane-1,3'(2'H)-phenanthren]-2-one, 1',4',4'a,9',10',10'a-hexahydro-7'-hydroxy-10'a-methyl-, (1R,4'aS,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-39-1 CAPLUS
CN Spiro[cyclobutane-1,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-, (4'aR,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-41-5 CAPLUS
CN Spiro[furan-2(3H),3'(2'H)-phenanthren]-7'-ol, 1',4,4',4'a,5,9',10',10'a-octahydro-10'a-methyl-, (2R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-42-6 CAPLUS
CN Spiro[furan-2(3H),3'(2'H)-phenanthren]-7'-ol, 1',4,4',4'a,5,9',10',10'a-octahydro-10'a-methyl-, (2R,4'aS,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-43-7 CAPLUS
CN Spiro[phenanthrene-3(2H),2'-[2H]pyran]-7-ol, 1,3',4,4',4a,5',6',9,10,10a-decahydro-10a-methyl-, (2'R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-44-8 CAPLUS
CN Spiro[phenanthrene-3(2H),2'-[2H]pyran]-7-ol, 1,3',4,4',4a,5',6',9,10,10a-decahydro-10a-methyl-, (2'R,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-45-9 CAPLUS
CN Spiro[furan-2(3H),3'(2'H)-phenanthren]-7'-ol, 1',4,4',4'a,5,9',10',10'a-octahydro-10'a-methyl-1'-(3-methylbutyl)-, (1'R,2S,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-46-0 CAPLUS
CN Spiro[cyclobutane-1,3'(2'H)-phenanthren]-7'-ol, 1',4',4'a,9',10',10'a-hexahydro-10'a-methyl-1'-(3-methylbutyl)-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-48-2 CAPLUS
CN Spiro[furan-2(3H),3'(2'H)-phenanthren]-7'-ol, 1',4,4',4'a,5,9',10',10'a-octahydro-10'a-methyl-1'-(3-methylbutyl)-, (1'R,2R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-49-3 CAPLUS
CN 2(1H)-Phenanthrenone, 10a-butyl-3,4,4a,9,10,10a-hexahydro-7-hydroxy-4a-methyl-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-55-1 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-4b,8-dimethyl- (9CI) (CA INDEX NAME)



RN 441331-62-0 CAPLUS
CN 2(1H)-Phenanthrenone, 1-ethyl-3,4,4a,9,10,10a-hexahydro-7-hydroxy-4a-methyl-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-65-3 CAPLUS
CN 2-Phenanthrenol, 8-butyl-4b,5,6,7,8,8a,9,10-octahydro-4b-methyl-,

10458286

(4bR,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-66-4 CAPLUS
CN 2-Phenanthrenol, 8-butyl-4b,5,6,7,8,8a,9,10-octahydro-4b-methyl-, (4bR,8S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-69-7 CAPLUS
CN 2(1H)-Phenanthrenone, 4a-butyl-3,4,4a,9,10,10a-hexahydro-7-hydroxy-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-70-0 CAPLUS
CN 2(1H)-Phenanthrenone, 4a-butyl-3,4,4a,9,10,10a-hexahydro-7-hydroxy-, (4aR,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10458286

RN 441331-72-2 CAPLUS
CN Spiro[1,3-dithiolane-2,2'(1'H)-phenanthren]-7'-ol, 3',4',4'a,9',10',10'a-hexahydro-4'a-methyl-, (4'aR,10'aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-73-3 CAPLUS
CN 2(1H)-Phenanthrenone, 3,4,4a,9,10,10a-hexahydro-7-hydroxy-4a-methyl-, oxime, (4aR,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



RN 441331-74-4 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-pentyl-, (4bR,6R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-75-5 CAPLUS
CN 2-Phenanthrenol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-pentyl-, (4bR,6S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-76-6 CAPLUS
CN 2(1H)-Phenanthrenone, 1-ethyl-3,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-, (1R,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441348-21-6 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-4-phenyl-, (4R,4aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **441332-20-3 441332-23-6**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenanthrenes for therapeutic use as selective estrogen receptor modulators)
RN 441332-20-3 CAPLUS
CN 2(1H)-Phenanthrenone, 3,4,4a,9,10,10a-hexahydro-7-methoxy-4a,10a-dimethyl- (9CI) (CA INDEX NAME)



RN 441332-23-6 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-10a-methyl-, (4aR,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **441331-50-6P 441331-83-5P 441331-84-6P**
441331-86-8P 441331-96-0P 441331-97-1P
441331-98-2P 441332-10-1P 441332-12-3P
441332-14-5P 441332-18-9P 441332-19-0P
441332-24-7P 441332-25-8P 441332-26-9P
441332-27-0P 441332-31-6P 441332-32-7P
441332-34-9P 441332-35-0P 441332-36-1P
441332-37-2P 441332-38-3P 441332-39-4P
441332-40-7P 441332-41-8P 441332-42-9P
441332-43-0P 441332-44-1P 441332-45-2P
441332-46-3P 441332-47-4P 441332-48-5P
441332-49-6P 441348-22-7P 441348-23-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenanthrenes for therapeutic use as selective estrogen receptor modulators)

RN 441331-50-6 CAPLUS
CN 2(1H)-Phenanthrenone, 10a-butyl-3,4,4a,9,10,10a-hexahydro-7-methoxy-4a-methyl-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-83-5 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-methoxy-,

10458286

(1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-84-6 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-methoxy-, (1R,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-86-8 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-methoxy-10a-methyl-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-96-0 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-methoxy-2-methyl-, (1R,2S,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-97-1 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-methoxy-2-methyl-, (1R,2R,4aS,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441331-98-2 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-7-methoxy-4-methyl-, (1R,4S,4aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-10-1 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-2,10a-dimethyl-1-(3-methylbutyl)-7-(phenylmethoxy)-, (1R,2R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-12-3 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-2,10a-dimethyl-1-(3-methylbutyl)-7-(phenylmethoxy)-, (1R,2S,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-14-5 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-10a-methyl-1-(3-methylbutyl)-7-(phenylmethoxy)-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-18-9 CAPLUS
CN 3(2H)-Phenanthrenone, 10a-ethyl-1,4,4a,9,10,10a-hexahydro-1-(3-methylbutyl)-7-(phenylmethoxy)-, (1R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-19-0 CAPLUS
CN 2(1H)-Phenanthrenone, 3,4,4a,9,10,10a-hexahydro-7-methoxy-4a,10a-dimethyl-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-24-7 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-10a-methyl-7-(phenylmethoxy)-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-25-8 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-10a-methyl-7-(phenylmethoxy)-, (4aR,10aS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-26-9 CAPLUS
CN 3-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-10a-methyl-3-pentyl-7-(phenylmethoxy)-, (3R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-27-0 CAPLUS
CN 3-Phenanthrenol, 1,2,3,4,4a,9,10,10a-octahydro-10a-methyl-3-pentyl-7-(phenylmethoxy)-, (3R,4aS,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-31-6 CAPLUS
CN 3(2H)-Phenanthrenone, 1-butyl-1,4,4a,9,10,10a-hexahydro-4,10a-dimethyl-7-(phenylmethoxy)-, (1R,4R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-32-7 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-7-hydroxy-4,10a-dimethyl-, (4R,4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-34-9 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-10a-methyl-7-(phenylmethoxy)-4,4-bis(phenylmethyl)-, (4aR,10aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-35-0 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-[1-(phenylsulfinyl)cyclopentyl]-, (4bR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-36-1 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-[3-(phenylmethoxy)propyl]-, (4bR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-37-2 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-6-(3-hydroxypropyl)-8a-methyl-, (4bR,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-38-3 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-[3-[[(4-methylphenyl)sulfonyl]oxy]propyl]-, (4bR,6R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-39-4 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-[3-[[(4-methylphenyl)sulfonyl]oxy]propyl]-, (4bR,6S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-40-7 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-6-(4-hydroxybutyl)-8a-methyl-, (4bR,6R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-41-8 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-6-(4-hydroxybutyl)-8a-methyl-, (4bR,6S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-42-9 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-[4-[[(4-methylphenyl)sulfonyl]oxy]butyl]-, (4bR,6R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-43-0 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-6-[4-[[(4-methylphenyl)sulfonyl]oxy]butyl]-, (4bR,6S,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-44-1 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-8-(3-methylbutyl)-6-[3-(phenylmethoxy)propyl]-, (4bR,6S,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-45-2 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-6-(3-hydroxypropyl)-8a-methyl-8-(3-methylbutyl)-, (4bR,6S,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-46-3 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-8-(3-methylbutyl)-6-[3-[[(4-methylphenyl)sulfonyl]oxy]propyl]-, (4bR,6S,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-47-4 CAPLUS
CN 2,6-Phenanthrenediol, 4b,5,6,7,8,8a,9,10-octahydro-8a-methyl-8-(3-methylbutyl)-6-[1-(phenylthio)cyclopropyl]-, (4bR,6S,8R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441332-48-5 CAPLUS
CN Spiro[cyclobutane-1,3'(2'H)-phenanthren]-2-one, 1',4',4'a,9',10',10'a-hexahydro-7'-hydroxy-10'a-methyl-1'-(3-methylbutyl)-, (1'R,4'aR,10'aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



10458286

RN 441332-49-6 CAPLUS
CN Dispiro[1,3-dithiolane-2,1'-cyclobutane-2',3''(2''H)-phenanthren]-7''-ol, 1'',4'',4''a,9'',10'',10''a-hexahydro-10''a-methyl-1''-(3-methylbutyl)-, (1''R,4''aR,10''aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 441348-22-7 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-10a-methyl-1-(3-methylbutyl)-7-(phenylmethoxy)-, (1S,4aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 441348-23-8 CAPLUS
CN 3(2H)-Phenanthrenone, 1,4,4a,9,10,10a-hexahydro-10a-methyl-1-(3-methylbutyl)-7-(phenylmethoxy)-, (1R,4aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:122822 CAPLUS
DN 136:161698
TI Combination preparation with an ERβ selective estrogen and a SERM or antiestrogen

10458286

IN Fritzemeier, Karl-Heinrich; Kollenkirchen, Uwe; Hegele-Hartung, Christa
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002011765	A1	20020214	WO 2001-EP9008	20010803
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10039199	A1	20020221	DE 2000-10039199	20000810
	AU 2001093720	A5	20020218	AU 2001-93720	20010803
	EP 1307229	A1	20030507	EP 2001-974107	20010803
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004505929	T2	20040226	JP 2002-517099	20010803
	US 2004053898	A1	20040318	US 2003-344161	20030926
PRAI	DE 2000-10039199	A	20000810		
	WO 2001-EP9008	W	20010803		

AB A novel medicament for the treatment of estrogen-deficient disease states is disclosed. Said medicament is a combination preparation comprising an ERβ-selective estrogen and an ERα-selective antiestrogen or SERM (Selective Estrogen Receptor Modulator). The antiestrogen or SERM which is a component of the combination preparation is preferably selective for the periphery. The preparation is suitable for an organ-specific estrogen therapy and has clear advantages over conventional therapies. Due to the combination of ERα-selective SERM and ERβ-estrogen the preparation permits a complete protection against bone loss caused by estrogen deficiency. The components of the medicament also have a synergistic effect with respect to the inhibition of inflammation inducing genes, in particular in inflammatory disorders such as atherosclerosis and arthritis, or neurodegenerative diseases such as Alzheimers and multiple sclerosis. Furthermore, pos. effects on cognition and mood may be expected. The protective estrogen-like effects are achieved, with no expectation of proliferation effects on breasts or uterus.

IT **397872-24-1D**, Estra-1,3,5(10)-triene-3,16-diol, derivs.
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination preparation with an ERβ selective estrogen and a SERM or antiestrogen)
RN 397872-24-1 CAPLUS
CN Estra-1,3,5(10)-triene-3,16-diol (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10458286

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:763027 CAPLUS
DN 135:318608
TI Preparation of 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens
IN Peters, Olaf; Hillisch, Alexander; Thieme, Ina; Elger, Walter; Hegele-Hartung, Christa; Kollenkirchen, Uwe; Fritzemeier, Karl-Heinrich; Patchev, Vladimir
PA Schering Aktiengesellschaft, Germany
SO PCT Int. Appl., 90 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001077139	A1	20011018	WO 2001-EP4290	20010412
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 10019167	A1	20011018	DE 2000-10019167	20000412
	CA 2406177	AA	20011018	CA 2001-2406177	20010412
	EP 1272504	A1	20030108	EP 2001-931609	20010412
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009983	A	20030225	BR 2001-9983	20010412
	JP 2003534248	T2	20031118	JP 2001-575609	20010412
	EE 200200589	A	20040415	EE 2002-589	20010412
	BG 107173	A	20030530	BG 2002-107173	20021008
	NO 2002004908	A	20021113	NO 2002-4908	20021011
	US 2003176405	A1	20030918	US 2003-257288	20030401
PRAI	DE 2000-10019167	A	20000412		
	US 2000-207370P	P	20000526		
	WO 2001-EP4290	W	20010412		

OS MARPAT 135:318608
GI



I



II



III

AB The invention relates to novel 8β-substituted estratrienes I [R2 = H, halogen, straight or branched (un)saturated C1-6-alkyl, alkoxy, CF3, sulfonamide; R3 = alkoxy, sulfonamide, acyloxy; R6, R7 = H; R6R7 = bond; R6', R7' = H, halogen, alkoxy, sulfonamide; R8 = a straight- or branched-chained, optionally partially or completely halogenated C1-5-alkyl, alkenyl, ethynyl, prop-1-ynyl; R9 = H, straight or branched (un)saturated C1-5-alkyl; R9R11 = bond; R11 = H; R11R12 = bond; R11' = H, halogen, a straight- or branched-chained, optionally partially or completely fluoro- or chloro-C1-4-alkyl, alkoxy, alkylthio; R12 = H; R14 = H; R14R15 = bond; R15 = H; R15R16 = bond; R15', R16' = H, halogen, alkoxy, sulfonamid; R16 = H; R17, R17' = H, H and halogen, H and OCH2Ph, H and sulfonamide, alkyl and acyl or acyloxy, alkoxy and alkyl, alkoxy and acyloxy; R17R17' = :CH2, :CR24R25;R24, R25 = halogen; R24R25 = O]. Thus, vinylestradiol II was prepared from estra-1,3,5(10)-tetraenone III in 8 steps. The inventive estratrienes are used as pharmaceutically active substances that have in vitro a higher affinity to estrogen receptor prepns. of rat prostate than to estrogen receptor prepns. of rat uterus, and which in vivo preferably have a preferential effect on bone material as compared to uterus and/or a pronounced effect with respect to the stimulation of the expression of 5HT2a receptor and transporter. II showed a relative binding affinity for the estrogen receptor of 1 in rat uterus and of 83 in rat prostate. The invention further relates to the production of these novel compds., to their use in therapy and to the pharmaceutical forms of administration that contain said novel compds. The invention further describes the use of said compds. for treating estrogen-deficiency related diseases and conditions and to the use of an 8β-substituted estratriene structural part in the overall structures of compds. that are characterized by a dissociation in favor of their estrogen effect on the bone as compared to the uterus.

IT **367264-79-7P 367264-81-1P 367264-83-3P**
367264-92-4P 367929-02-0P 367929-03-1P
367929-08-6P, 8β-Ethyl-9β-estra-1,3,5(10)-triene-3,17β-ol **367929-16-6P 367929-17-7P**
367929-18-8P 367929-19-9P 367929-20-2P
367929-21-3P 367929-22-4P 367929-23-5P
367929-24-6P 367929-25-7P 367929-26-8P
367929-27-9P 367929-28-0P 367929-29-1P

367929-30-4P 367929-31-5P 367929-32-6P
367929-33-7P 367929-34-8P, 8β-Vinyl-9β-estra-1,3,5(10)-triene-3,17β-diol
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens)

RN 367264-79-7 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethenyl-, 3-sulfamate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367264-81-1 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-(2,2-difluoroethenyl)-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367264-83-3 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-(1Z)-1-propenyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 367264-92-4 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-(1E)-1-propenyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 367929-02-0 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethenyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-03-1 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-08-6 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethyl-, (9β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-16-6 CAPLUS
CN Estra-1,3,5(10)-trien-17-ol, 8-(2,2-difluoroethenyl)-3-methoxy-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-17-7 CAPLUS
CN Estra-1,3,5(10)-trien-17-ol, 8-ethyl-3-methoxy-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-18-8 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethenyl-, disulfamate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-19-9 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethenyl-, 3-(acetylsulfamate), (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-20-2 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-[(aminosulfonyl)oxy]-8-ethenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-21-3 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-(acetyloxy)-8-ethenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-22-4 CAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, 8-ethenyl-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-23-5 CAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, 8-ethenyl-, 3-sulfamate, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-24-6 CAPLUS
CN Estra-1,3,5(10)-trien-17-one, 3-[(aminosulfonyl)oxy]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-25-7 CAPLUS
CN Estra-1,3,5(10)-triene-3,16,17-triol, 8-methyl-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-26-8 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-propyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-27-9 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethynyl-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-28-0 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 16-fluoro-8-methyl-, (16α,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-29-1 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-methyl-, (17α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-30-4 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethenyl-, diacetate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-31-5 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-methyl-, diacetate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-32-6 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethenyl-, 17-pentanoate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-33-7 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethenyl-, 17-acetate, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367929-34-8 CAPLUS
CN Estra-1,3,5(10)-triene-3,17-diol, 8-ethenyl-, (9β,17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **367264-73-1P 367264-74-2P 367264-75-3P 367264-80-0P 367264-82-2P 367264-91-3P 367279-41-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 8β-hydrocarbyl-substituted estratrienes for use as selective estrogens)
RN 367264-73-1 CAPLUS
CN Estra-1,3,5(10)-triene-8-carboxaldehyde, 3-methoxy-17-[(tetrahydro-2H-pyran-2-yl)oxy]-, (17β)- (9CI) (CA INDEX NAME)

10458286

Absolute stereochemistry.



RN 367264-74-2 CAPLUS
CN 2H-Pyran, 2-[[(17β)-8-ethenyl-3-methoxyestra-1,3,5(10)-trien-17-yl]oxy]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367264-75-3 CAPLUS
CN 2H-Pyran, 2-[[(17β)-8-ethyl-3-methoxyestra-1,3,5(10)-trien-17-yl]oxy]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10458286

RN 367264-80-0 CAPLUS
CN 2H-Pyran, 2-[[(17β)-8-(2,2-difluoroethenyl)-3-methoxyestra-1,3,5(10)-trien-17-yl]oxy]tetrahydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 367264-82-2 CAPLUS
CN 2H-Pyran, tetrahydro-2-[[(17β)-3-methoxy-8-(1Z)-1-propenylestra-1,3,5(10)-trien-17-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 367264-91-3 CAPLUS
CN 2H-Pyran, tetrahydro-2-[[(17β)-3-methoxy-8-(1E)-1-propenylestra-1,3,5(10)-trien-17-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 367279-41-2 CAPLUS
CN Estra-1,3,5(10)-triene-8-carbonitrile, 11-hydroxy-3-methoxy-17-[(tetrahydro-2H-pyran-2-yl)oxy]-, (17β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT